🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 75% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

2 Tablet(s) Serving Size
60 Servings
Multi-Vitamin and Mineral (MVM) Product Type
75% Evidence Coverage

Supplement Facts — Evidence Check

225 mcg (190% DV)
✅ 1.9× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.225mg
9 mcg (45% DV)
✅ Within RDA (0.6× RDA of 0.015 mg) 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.009mg UL 0.1mg
150 mg (35% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 150mg
Calcium
75 mg (6% DV)

Other Ingredients

Microcrystalline Cellulose Cellulose Stearic Acid Croscarmellose Sodium Magnesium Stearate Silicon Dioxide Pharmaceutical Glaze

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) No Allergies

Product Information

📋 Directions for Use

Directions: Take 2 tablets twice daily.

Dispose of container within 30 days of opening

⚠️ Warnings & Precautions

Warnings: Do not exceed suggested daily serving. If you are a competitive athlete, check with your sports association before using this product. Use only as directed.

Not for use by persons under the age of 18. Keep out of reach of children

Not for use by pregnant or nursing women. If you are taking medication, or have a medical condition, consult your physician before use.

Do not use if seal is broken or missing

🧪 Formulation Notes

Ultimate Nutrition's K2 + D3 is a key supplement for overall health and healthy aging. Vitamins K2 and D3 combine to help increase bone mineral density. Vitamin K2 can also reduce arterial calcification, while vitamin D3 improves calcium absorption. Calcium chelate works with K2 to strengthen bones and reduce the risk of fracture and magnesium chelate improves bone mineral content.

Allergen free!

Reduces arterial calcification by 50% Reduces bone fracture risk by 20% Increases bone mineral density by 3% Increases calcium absorption

Cardiovascular support Stronger bones Vitality series Nervous system health

Additional Information

Protect from heat, light, and moisture Store in a cool, dry place, 15-30 degrees C (59-86 degrees F)

Inspected FDA Facility Certified GMP Facility

Product Details

UPC / SKU 0 99071 87308 8
DSLD Entry Date 2023-07-18
Product Type Multi-Vitamin and Mineral (MVM)
Form Tablet or Pill
DSLD ID 293464
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →